App-Quantinova.ai

Association of Changes in Modifiable Factors with Changes in KidneyIntelXTM Scores in the CANVAS Participants with Prevalent Diabetic Kidney Disease

G. Nadkarni - International Society of Nephrology (ISN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Nephrology

Diabetic nephropathy

Canagliflozin

Prediction of 3-Year Risk of Diabetic Kidney Disease Using Machine Learning Based on Electronic Medical Records

Z. Dong - International Society of Nephrology (ISN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Diabetic nephropathy

N/A

DEVELOPMENT OF BIOMARKERS FOR PREDICTING DKD PROGRESSION IN NON-PROTEINURIC TYPE 2 DIABETES: THE NTUH-DKD COHORT STUDY

L.M. Chuang - International Society of Nephrology (ISN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

N/A

POST TRANSPLANTATION DIABETES MELLITUS: DIAGNOSIS AND MANAGEMENT

N. ben aicha - International Society of Nephrology (ISN) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetes

N/A

Case-Control Investigation of Critically Ill Patients with Newly Diagnosed Diabetes: Clinical Characteristics, Glucose Metrics and Outcomes

Y. Wang - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Diabetic ketoacidosis

N/A

Type 1 Diabetes Leads to Decline in Lung Function and Restrictive Pulmonary Defects

S. S. Park - American Thoracic Society (ATS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Type 1 diabetes mellitus

Streptozotocin

Protective potential of laughter yoga and clapping exercise on stress level and motor functions in Parkinson’s disease patients with type 2 diabetes

R. Singh - International Congress of Parkinson's Disease and Movement Disorders (MDS) , 2023

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Parkinson's disease

N/A

Investigating factors associated with the prevalence of IHD among uncontrolled diabetic patients

S Shaharuddin - European Society of Cardiology (ESC) , 2023

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

Type 2 diabetes mellitus

N/A

Estimated glucose disposal rate, a novel biomarker for insulin sensitivity, predicts risk for incident heart failure in patients with type 2 diabetes

J J Liu - European Society of Cardiology (ESC) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Type 2 diabetes mellitus

Insulin

HbA1c variability is associated with adverse outcomes in heart failure patients with and without diabetes

X Xu - European Society of Cardiology (ESC) , 2023

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Fetal Hemoglobin Induced Improvement in Relative Age of Sickle Red Blood Cells Determined through Glycated Hemoglobin Assessment By Flow Cytometry

Nassima Djouder - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

A First-in-Human Phase 1 Study of Abbv-319, an Antibody-Drug Conjugate Composed of a CD19 Antibody Linked to a Potent Proprietary Glucocorticoid Receptor Modulator, in Patients with Relapsed or Refractory B-Cell Malignancies

Moshe Levy - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Waldenstrom’s macroglobulinemia

Glucocorticoid

Clinical Course and Outcomes in Older Patients with Sickle Cell Disease at a Community Hospital

Frederic Karim - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

Chronic kidney disease

Proglumide

Metformin Use and Incidence of Cancer: A Large Retrospective Cohort Study of U.S. Veterans

Maya Abdallah - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Multiple Myeloma

Metformin controlled release

The Impact of Glycemic Control in Thrombo-Inflammatory Biomarkers in Diabetic Pulmonary Embolism Patients

Bulent Kantarcioglu - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Vasodilation dysfunction

Hemostatic Solution

The Role of Blood Cellular Indices in Diabetic Pulmonary Embolism Patients in Predicting Adverse Outcomes

Bulent Kantarcioglu - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Myocardial infarction

N/A

Restless Legs Syndrome (RLS) in Patients (pts) with Polycythemia Vera (PV): Is Iron Deficiency (ID) the Only Culprit?

Duygu Seyhan Erdoğan - American Society of Hematology (ASH) , 2022

Therapeutic Area

Disease

Drug/Treatment

Peripheral Nervous System

Restless Legs syndrome

Cyanocobalamin

Changes in metabolic health at a community hospital-based pediatric clinic during the COVID-19 pandemic

Ishita Kharode - Pediatric Academic Societies (PAS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Coronavirus disease

N/A

Increased prevalence of pre-diabetes among children with overweight/obesity and elevated blood pressure

Rashmi Pashankar - Pediatric Academic Societies (PAS) , 2022

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Left ventricular hypertrophy

Metformin Hydrochloride

Filters

4759 Abstracts